Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds

 
• By Alaric DeArment
  
Gilead's magrolimab is mostly back on track after the FDA lifted a partial hold on two key indications • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D